Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.
Company Growth (employees)
Type
Public
HQ
Woodcliff Lake, US
Size (employees)
77 (est)+15%
Eagle Pharmaceuticals is headquartered in Woodcliff Lake, US

Key People/Management at Eagle Pharmaceuticals

Scott L. Tarriff

Scott L. Tarriff

President

Eagle Pharmaceuticals Office Locations

Eagle Pharmaceuticals has offices in Woodcliff Lake, Orlando, San Francisco, Chicago and in 15 other locations
Woodcliff Lake, US (HQ)
50 Tice Blvd, Suite 315
Show all (19)

Eagle Pharmaceuticals Financials and Metrics

Eagle Pharmaceuticals Financials

Eagle Pharmaceuticals's revenue was reported to be $76.8 m in Q1, 2017
USD

Revenue (Q1, 2017)

76.8 m

Gross profit (Q1, 2017)

66 m

Gross profit margin (Q1, 2017), %

86%

Net income (Q1, 2017)

22.9 m

EBIT (Q1, 2017)

32.7 m

Market capitalization (17-Oct-2017)

799.5 m

Cash (31-Mar-2017)

27.7 m
Eagle Pharmaceuticals's current market capitalization is $799.5 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

19.1 m66.2 m189.5 m

Revenue growth, %

247%186%

Cost of goods sold

1.8 m

Gross profit

187.7 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6 m5.7 m29.6 m40.9 m37.8 m76.8 m

Cost of goods sold

3.3 m3.8 m14.6 m11.5 m10.4 m10.8 m

Gross profit

2.7 m2 m15 m29.4 m27.4 m66 m

Gross profit Margin, %

44%35%51%72%72%86%
USDFY, 2014FY, 2015FY, 2016

Cash

34.9 m79.1 m52.8 m

Accounts Receivable

12 m26.3 m42.2 m

Inventories

1.2 m15 m11.4 m

Current Assets

49.7 m122.3 m109.1 m
USDQ1, 2017

Cash

27.7 m

Accounts Receivable

84.7 m

Inventories

3 m

Current Assets

123.6 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(18 m)2.6 m81.5 m

Depreciation and Amortization

13 k

Accounts Receivable

(2.2 m)(14.3 m)(15.9 m)

Inventories

(1.3 m)(13.8 m)12.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.2 m)(10.2 m)(896 k)13.1 m12 m22.9 m

Accounts Receivable

7.8 m6.7 m10.5 m13 m12.2 m26.5 m52 m47.1 m84.7 m

Inventories

329 k2 m2.3 m7.3 m7.8 m6.4 m7.1 m3 m

Accounts Payable

2.5 m2.5 m5.4 m4.8 m14.1 m10.3 m11.4 m13.1 m19 m
USDY, 2017

Revenue/Employee

1.1 m

Financial Leverage

1.3 x
Show all financial metrics

Eagle Pharmaceuticals Market Value History

Traffic Overview of Eagle Pharmaceuticals

Eagle Pharmaceuticals Online and Social Media Presence

Eagle Pharmaceuticals Company Life and Culture

You may also be interested in